EpiPen Maker May Have Cheated Government Out Of Millions Of Dollars

Mylan has been accused of classifying EpiPens as a generic drug to pay a smaller rebate to Medicaid.
EpiPen Maker May Have Cheated Government Out Of Millions Of Dollars

Mylan's found itself in another EpiPen scandal; only this time, the company may have overcharged the U.S. government.

On Wednesday, two members of Congress accused Mylan of misclassifying its emergency allergy medication as a generic drug so it could pay less in rebates to Medicaid. 

SEE MORE: Lawmaker Says Mylan's Lobbying Opened The Door For EpiPen Scrutiny

Instead of paying a 23 percent rebate for a brand-name drug, Mylan has been paying a 13 percent rebate. That amounts to millions of dollars less to the government and taxpayers who need the drug.

At the same time, Mylan raised the price of a single pen to roughly $300 this year. 

Mylan may have a harder time arguing EpiPens fall under the generic drug category, since during the height of its previous price scandal, the company said it would start selling a generic version of EpiPens for half-price. 

Featured Stories
Vice President Mike Pence

Mike Pence Calls On Conservatives To Mobilize In CPAC Speech

Producer Nicole Amarteifio smiling at her Ghana studio

Meet The Woman Who's Been Called The 'Issa Rae Of West Africa'

Prison inmates sit at tables

Private Prisons Will Make A Comeback In The Trump Administration

Want to see more stories like this?
Like Newsy on Facebook for More Business Coverage